Last reviewed · How we verify
AB002 Dose 1
AB002, developed by Aronora, Inc., is a novel therapeutic agent currently under investigation for various indications including Alzheimer's disease and end-stage renal disease. The drug has completed Phase 1 and Phase 2 trials, demonstrating promising safety and efficacy profiles. Further clinical development is needed to confirm its potential as a treatment option.
At a glance
| Generic name | AB002 Dose 1 |
|---|---|
| Also known as | E-WE thrombin Dose 1, E-WE thrombin Dose 2 |
| Sponsor | Aronora, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB002 Dose 1 CI brief — competitive landscape report
- AB002 Dose 1 updates RSS · CI watch RSS
- Aronora, Inc. portfolio CI